Charles River And INADcure Announce Gene Therapy Manufacturing Collaboration
Portfolio Pulse from Happy Mohamed
Charles River Laboratories (NYSE:CRL) and INADcure Foundation announced a collaboration for plasmid DNA manufacturing in support of Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy (INAD). Charles River's CDMO expertise will be leveraged for HQ plasmid production.
June 08, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories partners with INADcure Foundation for plasmid DNA manufacturing, leveraging its CDMO expertise for INAD clinical trials.
The collaboration with INADcure Foundation will leverage Charles River's CDMO expertise in HQ plasmid DNA production, potentially leading to positive outcomes in the clinical trials for INAD. This partnership can enhance Charles River's reputation and potentially lead to more collaborations, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100